API | axomadol

axomadol Report issue

Small molecule Experimental

AACT ChEMBL PubChem

Active Ingredient History

NOW

Axomadol is a synthetic, centrally-acting opioid analgesic of the benzenoid class which was under investigation by Endo Pharmaceuticals in collaboration with Grünenthal for the treatment of chronic, moderate to severe lower back pain and arthrosis. Development was halted after phase II clinical trials as it did not meet the pre-determined clinical endpoints. ^Wikipedia

Chemistry

SMILES: COc1cccc(c1)C2(O)CC(O)CCC2CN(C)C
InChIKey: LQJLLAOISDVBJM-UHFFFAOYSA-N
Mol. Mass: 279.38
ALogP: 1.61 Partition coefficient
ChEMBL Molecules:

axomadol

None

More Chemistry

Pharmacology

Mechanisms of Action:
- Delta-type opioid receptor (Homo sapiens) ^UniProt
- Kappa-type opioid receptor (Homo sapiens) ^UniProt
- Mu-type opioid receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

axomadol | bn110 base | en-3324 | grt-0151y | grt151 base

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Acute Pain (Phase 1)

Back Pain (Phase 2)

Chronic Pain (Phase 1)

Pain (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue